Latest Safety News

An independent meta-analysis presented at the ASH Annual Meeting reveals Mesoblast’s remestemcel-L achieves superior remission rates and safety outcomes compared to ruxolitinib in treating steroid-refractory acute graft-versus-host disease.

HITIQ has secured a prestigious grant from the Australian Sports Commission to enhance its PROTEQT™ brain health monitoring technology, positioning the company for wider adoption across elite and community sports.

EBR Systems has completed the first patient implant in its Totally Leadless CRT (TLC-AU) feasibility study, marking a strategic step toward expanding wireless cardiac resynchronisation therapy for heart failure patients.

Boom Logistics has appointed Lester Fernandez as its permanent Managing Director and CEO, entrusting him to lead the company through its next phase of growth with a strong focus on safety and operational excellence.

EV Resources has cleared a key technical review of its Tecomatlán processing plant in Mexico, setting the stage for near-term antimony concentrate production and pilot testing for its Los Lirios project.

Neurizon Therapeutics has secured FDA clearance for its lead drug candidate NUZ-001 to enter the HEALEY ALS Platform Trial, marking a key regulatory milestone and setting the stage for patient enrollment in early 2026.

Lindian Resources has awarded all major non-process infrastructure contracts for its Kangankunde Rare Earths Project in Malawi, marking a pivotal step toward first production in late 2026. Construction is underway with strong schedule confidence and capital discipline.

InhaleRx advances its clinical pipeline with a new oral treatment for resistant depression and plans a strategic rebrand to Nexalis Therapeutics, signaling a broader focus beyond inhaled therapies.

Beacon Minerals reports strong assay results from its ongoing drill program at the Iguana Deposit, alongside securing vital land use and mining approvals, advancing the Lady Ida Project towards production.

Immutep has struck a strategic licensing deal with Dr. Reddy’s, granting rights to commercialise its novel cancer immunotherapy Eftilagimod Alfa across key emerging markets. The agreement includes a $20 million upfront payment and potential milestones exceeding $349 million.

Memphasys is intensifying its direct sales efforts for the Felix™ sperm-selection device across key Middle East IVF clinics, positioning for rapid market activation upon CE Mark approval expected early 2026.

Meteoric Resources is poised for a critical environmental milestone as the Preliminary Environmental Licence for its Caldeira Rare Earth Project is set for approval at the upcoming COPAM meeting. This step could unlock the path to construction and keep the project timeline intact.